Navigation Links
Genta Incorporated Announces Second Quarter 2008 Financial Results and Corporate Highlights
Date:8/7/2008

0.9 million for the six months ended June 30, 2008, compared with $7.5 million for the six months ended June 30, 2007. This increase was primarily due to the recognition in March 2008 of $2.5 million for license payments on tesetaxel and higher expenses from the AGENDA clinical trial, partially offset by lower payroll costs.

Selling, general and administrative expenses were $2.6 million for the second quarter of 2008, compared with $4.7 million for the second quarter of 2007, and $6.2 million for the six months ended June 30, 2008, compared with $8.8 million for the six months ended June 30, 2007. These decreases were primarily due to lower payroll costs, resulting from the two workforce reductions, as well as lower administrative expenses.

In May 2008, to reduce its ongoing expenses, the Company reduced its office space. The Company's landlord received a termination payment of $1.3 million, comprised of security deposits, and will receive a future payment of $2.0 million upon the earlier of July 1, 2009 or the Company's completion of a business development transaction that exceeds $5.0 million in upfront cash. This agreement resulted in an incremental $3.3 million in expenses for the second quarter and six months ended June 30, 2008.

In the fourth quarter of 2006, the Company recorded an expense of $5.3 million that provides for the issuance of 2.0 million shares of Genta common stock, for a settlement in principle of class action litigation. This liability was marked to market until the date that the settlement became final on June 27, 2008. Changes in the price of Genta's common stock resulted in income of $0.1 million in the second quarter of 2008, compared with $0.2 million in the second quarter of 2007, and income of $0.3 million for the six months ended June 30, 2008, compared with $1.8 million for the six months ended June 30, 2007.

On June 5, 2008, the Company entered into a securities purchase agreement with certain institutiona
'/>"/>

SOURCE Genta Incorporated
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10

Related biology technology :

1. Genta Announces Second Quarter 2008 Financial Results and Conference Call
2. Genta Receives Notice of Allowances for European Patents Related to Composition and Processes for Tesetaxel, a Leading Oral Taxane
3. Genta Submits NDA Amendment to FDA for Genasense as Treatment of Chronic Lymphocytic Leukemia
4. Genta Secures Up to $40 Million Convertible Financing Facility to Fund Key Programs
5. Genta Incorporated Announces First Quarter 2008 Financial Results and Corporate Highlights
6. Genta Announces Transfer of its Common Stock to the OTC Bulletin Board
7. Genta Announces Pending Transfer of its Common Stock to the Over-the-Counter Bulletin Board
8. Dr. Elizabeth Brown Joins Argenta TEC
9. Syngenta To Build Major Global Biotech Research Center in Beijing, China
10. Genta Restructures Operations to Focus on Priority Initiatives
11. Genta Granted Extension to Achieve Compliance with NASDAQ Listing Requirements
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/24/2014)... 2014  Rock Creek Pharmaceuticals, Inc., (NASDAQ: ... Clinical Trial Application (CTA) with the United ... seeking regulatory approval to initiate clinical trials for the ... Contingent on the Company receiving CTA regulatory approval, ... to assess the safety, tolerability and dose escalation of ...
(Date:12/22/2014)... , Dec. 22, 2014   Synthetic ... developer of pathogen-specific therapies for serious infections ... the microbiome, today announced positive topline safety ... clinical trial of SYN-004, the Company,s investigational ... Clostridium difficile (C. difficile) infection, ...
(Date:12/22/2014)... , Dec. 22, 2014 GenomeDx Biosciences today ... Prostate Cancer Classifier, a genomic test for prostate cancer, ... high-risk men managed by radical prostatectomy without adjuvant therapy. ... is relatively uncommon, using tumor genomics to identify these ... disease is an important advance. The study has been ...
(Date:12/22/2014)... ITRA Global, one of the largest organizations ... estate, has further expanded its global reach with the ... Western Australia, reports Mylinda Vick, CCIM, Chairman of the ... / ACORPP (Australian Corporate Property and Projects) , is ... services to a wide range of clients in the ...
Breaking Biology Technology:Rock Creek Pharmaceuticals Files Clinical Trial Application in the UK for Clinical Trials of Anatabine Citrate Formulations 2Rock Creek Pharmaceuticals Files Clinical Trial Application in the UK for Clinical Trials of Anatabine Citrate Formulations 3Synthetic Biologics Announces Positive Topline Results from Phase 1a Trial of SYN-004 for the Prevention of C. difficile Infection 2Synthetic Biologics Announces Positive Topline Results from Phase 1a Trial of SYN-004 for the Prevention of C. difficile Infection 3Synthetic Biologics Announces Positive Topline Results from Phase 1a Trial of SYN-004 for the Prevention of C. difficile Infection 4Synthetic Biologics Announces Positive Topline Results from Phase 1a Trial of SYN-004 for the Prevention of C. difficile Infection 5Study Published in European Urology Shows that the Decipher Prostate Cancer Classifier is Predictive of Rapid Metastasis in High-Risk Men who have had Prostate Surgery 2Study Published in European Urology Shows that the Decipher Prostate Cancer Classifier is Predictive of Rapid Metastasis in High-Risk Men who have had Prostate Surgery 3ITRA Global Continues International Expansion in Perth and Brisbane, Australia 2
... CALGARY, May 22 /PRNewswire-FirstCall/ - Oncolytics Biotech ... has,successfully transferred cGMP production for REOLYSIN(R) at ... Division of Sigma-Aldrich Corporation.,This follows the successful ... announced,by the Company last year., Yields ...
... AMSTERDAM, The Netherlands, May 22 Amsterdam,Molecular ... field of human gene,therapy, today announced that ... in Rome, Italy, to their advanced small ... of Duchenne,muscular dystrophy (DMD). The combination with ...
... SOUTH SAN FRANCISCO, Calif., May 21 Exelixis,Inc. (Nasdaq: ... and,analyst briefing in conjunction with the 44th Annual Meeting of ... 8:00 p.m. CT,on Monday, June 2, 2008., Participants:, ... Officer -- Michael M. Morrissey, PhD, President of Research ...
Cached Biology Technology:Oncolytics Biotech Inc. Transfers 40-Litre cGMP Manufacturing Process for REOLYSIN(R) 2Oncolytics Biotech Inc. Transfers 40-Litre cGMP Manufacturing Process for REOLYSIN(R) 3AMT Accesses Technology for Treatment of Duchenne Muscular Dystrophy 2AMT Accesses Technology for Treatment of Duchenne Muscular Dystrophy 3Exelixis Announces June 2 Webcast of Its ASCO Investor and Analyst Briefing 2Exelixis Announces June 2 Webcast of Its ASCO Investor and Analyst Briefing 3Exelixis Announces June 2 Webcast of Its ASCO Investor and Analyst Briefing 4
(Date:12/11/2014)... , Dec. 09, 2014 Research and ... ( http://www.researchandmarkets.com/research/twhjll/biometrics_market ) has ... in the APAC Region 2015-2019"  report to their ... in this market is advances in technology. With ... upgrade biometric solutions to the latest standard that ...
(Date:12/11/2014)... , Dec. 10, 2014  Data Sciences ... monitoring, has released a new series of digital ... preclinical toxicology researchers. M series, part of the ... collect the best possible physiologic data when incorporating ... Adding functional endpoints to toxicology studies has evolved ...
(Date:12/10/2014)... , Dec. 9, 2014  Wake Forest Baptist Medical Center ... for its School of Medicine. Funding for this $50 ... campaign that will be publicly launched next summer. ... in the former 60 series R.J. Reynolds Tobacco Company ... Construction will begin immediately with plans to be ready ...
Breaking Biology News(10 mins):Biometrics Market in the APAC Region 2015-2019: Key Vendors are 3M Cogent, NEC, Safran and Suprema 2New telemetry implants expected to change how large animal toxicology studies are conducted 2Wake Forest Baptist to Build New Medical Education Facility In Wake Forest Innovation Quarter 2Wake Forest Baptist to Build New Medical Education Facility In Wake Forest Innovation Quarter 3Wake Forest Baptist to Build New Medical Education Facility In Wake Forest Innovation Quarter 4
... world,s subspecies of tigers are now extinct. A new study ... a result of human activities, particularly the conversion of natural ... The study, conducted by Virginia Tech and World Wildlife ... investigate the use of different land cover types not ...
... February 29, 2012 A revealing study published in ... epilepsy is not faring well in social media. Kate McNeil ... from Twitter to provide a snapshot of how epilepsy is ... platform launched in 2006, allows its users to communicate through ...
... Wednesday, Feb. 29, 2012, Cleveland: Cleveland Clinic Children,s Hospital ... can be used to help identify children who are ... is designed to confirm the predictive value of established ... that have been completed. Thomas Frazier, Ph.D., of ...
Cached Biology News:Nowhere to hide: Study finds future of Sumatran tigers threatened by human disturbances 2Nowhere to hide: Study finds future of Sumatran tigers threatened by human disturbances 3Is Twitter reinforcing negative perceptions of epilepsy? 2Cleveland Clinic Children's Hospital launches study to genetically test for autism 2
MOUSE ANTI RABBIT T LYMPHOCTYES Immunogen: Rabbit Thymocytes...
Normal canine serum collected from healthy normal canines....
RABBIT ANTI HUMAN CYTOCHROME P450 1A1/2 Immunogen: Purified human CYP1A2 expressed in E.Coli ...
... of BAC (100+kb), fosmid (40kb), and large ... than any othe BAC vector. On command ... and easy recombinant DNA purification. Available with ... VC) vectors for the highest insert stability. ...
Biology Products: